Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


30.04.2018

1 Am J Respir Cell Mol Biol
1 Ann Oncol
1 Ann Thorac Surg
1 Anticancer Res
1 Br J Cancer
3 Cancer Lett
1 Cancer Res
1 Cancer Sci
1 Chest
1 Clin Cancer Res
2 Clin Lung Cancer
1 Eur Respir J
3 Int J Radiat Oncol Biol Phys
1 J Cancer Res Clin Oncol
1 J Natl Cancer Inst
2 J Thorac Cardiovasc Surg
3 J Thorac Oncol
1 Lancet Respir Med
1 Lung Cancer
1 Nat Med
1 Oncogene
1 Oncol Rep
2 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Respir Cell Mol Biol

  1. DEVLIN JR, Verschuren EW
    More than a Tumor Suppressor: E-Cadherin Loss Drives Lung Cancer Metastasis.
    Am J Respir Cell Mol Biol. 2018 Apr 24. doi: 10.1165/rcmb.2018-0063.
    PubMed     Text format    


    Ann Oncol

  2. DACIC S
    Time is up for PD-L1 testing standardization in lung cancer.
    Ann Oncol. 2018;29:791-792.
    PubMed     Text format    


    Ann Thorac Surg

  3. SANGANI NK, Naliath SM
    Pseudomesotheliomatous Type of Sarcomatoid Squamous Cell Lung Cancer Presenting With Hemothorax.
    Ann Thorac Surg. 2018 Apr 21. pii: S0003-4975(18)30546.
    PubMed     Text format     Abstract available


    Anticancer Res

  4. MATSUMOTO N, Kumasaka A, Ando T, Komiyama K, et al
    Detection of EGFR Gene Mutation by Mutation-oriented LAMP Method.
    Anticancer Res. 2018;38:2093-2099.
    PubMed     Text format     Abstract available


    Br J Cancer

  5. BINS S, Basak EA, El Bouazzaoui S, Koolen SLW, et al
    Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients.
    Br J Cancer. 2018 Apr 26. pii: 10.1038/s41416-018-0074.
    PubMed     Text format     Abstract available


    Cancer Lett

  6. TAN W, Liao Y, Qiu Y, Liu H, et al
    miRNA 146a promotes chemotherapy resistance in lung cancer cells by targeting DNA damage inducible transcript 3 (CHOP).
    Cancer Lett. 2018 Apr 24. pii: S0304-3835(18)30295.
    PubMed     Text format     Abstract available

  7. YU F, Liu JB, Wu ZJ, Xie WT, et al
    Tumor suppressive microRNA-124a inhibits stemness and enhances gefitinib sensitivity of non-small cell lung cancer cells by targeting ubiquitin-specific protease 14.
    Cancer Lett. 2018 Apr 24. pii: S0304-3835(18)30289.
    PubMed     Text format     Abstract available

  8. ZHAO X, Wu X, Qian M, Song Y, et al
    Knockdown of TGF-beta1 expression in human umbilical cord mesenchymal stem cells reverts their exosome-mediated EMT promoting effect on lung cancer cells.
    Cancer Lett. 2018 Apr 24. pii: S0304-3835(18)30293.
    PubMed     Text format     Abstract available


    Cancer Res

  9. HEIM L, Friedrich J, Engelhardt M, Trufa DI, et al
    NFATc1 promotes anti-tumoral effector functions and memory CD8+ T cell differentiation during non-small cell lung cancer development.
    Cancer Res. 2018 Apr 24. pii: 0008-5472.CAN-17-3297.
    PubMed     Text format     Abstract available


    Cancer Sci

  10. AKAMATSU H, Katakami N, Okamoto I, Kato T, et al
    Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small cell lung cancer: AURA3 trial.
    Cancer Sci. 2018 Apr 26. doi: 10.1111/cas.13623.
    PubMed     Text format     Abstract available


    Chest

  11. MUTHU V, Sehgal IS, Dhooria S, Aggarwal AN, et al
    Efficacy of endosonographic procedures in mediastinal re-staging of lung cancer after neoadjuvant therapy: A systematic review and diagnostic accuracy meta-analysis.
    Chest. 2018 Apr 20. pii: S0012-3692(18)30585-3. doi: 10.1016/j.chest.2018.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  12. CLARET L, Jin JY, Ferte C, Winter H, et al
    A model of overall survival predicts treatment outcomes with atezolizumab vs chemotherapy in non-small cell lung cancer based on early tumor kinetics.
    Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-17-3662.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  13. KIM CR, Kim B, Ning MS, Reddy JP, et al
    Cost Analysis of PET/CT Versus CT as Surveillance for Stage III Non-Small-Cell Lung Cancer After Definitive Radiation Therapy.
    Clin Lung Cancer. 2018 Mar 17. pii: S1525-7304(18)30054.
    PubMed     Text format     Abstract available

  14. GIACCONE G, Sanborn RE, Waqar SN, Martinez-Marti A, et al
    A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation.
    Clin Lung Cancer. 2018 Mar 23. pii: S1525-7304(18)30058.
    PubMed     Text format     Abstract available


    Eur Respir J

  15. RAMI-PORTA R, Call S, Dooms C, Obiols C, et al
    Lung cancer staging: a concise update.
    Eur Respir J. 2018 Apr 26. pii: 13993003.00190-2018.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  16. TSENG YD, Cutter DJ, Plastaras JP, Parikh RR, et al
    Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee.
    Int J Radiat Oncol Biol Phys. 2017 Sep 21. pii: S0360-3016(17)30901.
    PubMed     Text format    

  17. NANTAVITHYA C, Gomez DR, Wei X, Komaki R, et al
    Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2018 Mar 2. pii: S0360-3016(18)30316.
    PubMed     Text format     Abstract available

  18. LEE SH, Rimner A, Gelb E, Deasy JO, et al
    Correlation Between Tumor Metabolism and Semiquantitative Perfusion Magnetic Resonance Imaging Metrics in Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2018 Mar 2. pii: S0360-3016(18)30330.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  19. FAEHLING M, Achenbach J, Staib P, Steffen U, et al
    Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC).
    J Cancer Res Clin Oncol. 2018 Apr 23. pii: 10.1007/s00432-018-2649.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  20. NABI H, Provencher L, Diorio C
    RE: Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424).
    J Natl Cancer Inst. 2018 Apr 20. pii: 4980806. doi: 10.1093.
    PubMed     Text format    


    J Thorac Cardiovasc Surg

  21. AJMANI GS, Wang CH, Kim KW, Howington JA, et al
    Surgical quality of wedge resection affects overall survival in patients with early stage non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2018 Mar 13. pii: S0022-5223(18)30776.
    PubMed     Text format     Abstract available

  22. KRUSER TJ, Mohindra N, DeCamp MM
    One size does not fit all: Nuances in postoperative N2 non-small cell lung cancer management.
    J Thorac Cardiovasc Surg. 2018 Mar 29. pii: S0022-5223(18)30865.
    PubMed     Text format    


    J Thorac Oncol

  23. WADE S, Weber M, Caruana M, Kang YJ, et al
    Estimating the cost-effectiveness of lung cancer screening with low dose computed tomography for high risk smokers in Australia.
    J Thorac Oncol. 2018 Apr 21. pii: S1556-0864(18)30531.
    PubMed     Text format     Abstract available

  24. VAN VEGGEL B, de Langen AJ, Hashemi S, Monkhorst K, et al
    Brief report: Afatinib and cetuximab in four patients with EGFR exon 20 insertion positive advanced non-small-cell lung cancer.
    J Thorac Oncol. 2018 Apr 24. pii: S1556-0864(18)30538.
    PubMed     Text format     Abstract available

  25. SCHILD SE, Fan W, Stinchcombe TE, Vokes EE, et al
    Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Apr 21. pii: S1556-0864(18)30537.
    PubMed     Text format     Abstract available


    Lancet Respir Med

  26. THE LANCET RESPIRATORY MEDICIN
    Lung cancer immunotherapy biomarkers: refine not reject.
    Lancet Respir Med. 2018 Apr 23. pii: S2213-2600(18)30180.
    PubMed     Text format    


    Lung Cancer

  27. YEN CC, Su HC, Chu CY, Lai SJ, et al
    Excellent treatment response with pembrolizumab in a lung cancer patient who developed immune-mediated acute motor/sensory axonal polyneuropathy.
    Lung Cancer. 2018 Apr 17. pii: S0169-5002(18)30342.
    PubMed     Text format    


    Nat Med

  28. ROBICHAUX JP, Elamin YY, Tan Z, Carter BW, et al
    Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
    Nat Med. 2018 Apr 23. pii: 10.1038/s41591-018-0007.
    PubMed     Text format     Abstract available


    Oncogene

  29. WANG S, Jia M, He Z, Liu XS, et al
    APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer.
    Oncogene. 2018 Apr 26. pii: 10.1038/s41388-018-0245.
    PubMed     Text format     Abstract available


    Oncol Rep

  30. DING J, Jia X, Zuo B, He J, et al
    A novel monoclonal antibody targeting a novel epitope of VEcadherin inhibits vasculogenic mimicry of lung cancer cells.
    Oncol Rep. 2018 Apr 16. doi: 10.3892/or.2018.6374.
    PubMed     Text format     Abstract available


    PLoS One

  31. LIU K, Zheng D, Xu G, Du Z, et al
    Correction: Local thoracic therapy improve prognosis for stage IV non-small cell lung cancer patients combined with chemotherapy: A Surveillance, Epidemiology, and End Results database analysis.
    PLoS One. 2018;13:e0196618.
    PubMed     Text format     Abstract available

  32. BISAGNI A, Pagano M, Maramotti S, Zanelli F, et al
    Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients.
    PLoS One. 2018;13:e0196350.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: